New terms for Precision BioSciences' collaboration with Lilly's Prevail

10 July 2023

US gene editing company Precision BioSciences (Nasdaq: DTIL) and Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly (NYSE: LLY), have amended and restated the development and license agreement that they signed in November 2020.

The companies will continue to collaborate on developing Precision’s ARCUS nucleases for the research and development of potential in vivo therapies for genetic disorders, including Duchenne muscular dystrophy and two additional gene targets. Prevail also continues to have the right to nominate up to three additional gene targets for genetic disorders.

Prevail will oversee and fund pre-clinical research and investigational new drug (IND) application-enabling activities following creation, selection, in vivo development, and optimization of ARCUS nucleases with respect to the gene targets subject to the collaboration, which were previously conducted by Precision at its expense.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK